Expert forum
首頁(yè) 專(zhuān)家論壇 標(biāo)本專(zhuān)家Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.
登錄注冊(cè)
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.
2017-12-08 07:00來(lái)源:原版作者:Baccelli I
It has been hypothesized that carcinoma metastasis is initiated by a subpopulation of circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of CTCs is an indicator of poor prognosis in several carcinoma entities, the existence and phenotype of metastasis-initiating cells (MICs) among CTCs has not been experimentally demonstrated. Here we developed a xenograft assay and used it to show that primary human luminal breast cancer CTCs contain MICs that give rise to bone, lung and liver metastases in mice. These MIC-containing CTC populations expressed EPCAM, CD44, CD47 and MET. In a small cohort of patients with metastases, the number of EPCAM(+)CD44(+)CD47(+)MET(+) CTCs, but not of bulk EPCAM(+) CTCs, correlated with lower overall survival and increased number of metastasic sites. These data describe functional circulating MICs and associated markers, which may aid the design of better tools to diagnose and treat metastatic breast cancer.
版權(quán)聲明:
本網(wǎng)站所有注明“來(lái)源:“陽(yáng)普醫(yī)療”的文字、圖片和音視頻資料,版權(quán)均屬于陽(yáng)普醫(yī)療所有,非經(jīng)授權(quán),任何媒體、網(wǎng)站或個(gè)人不得轉(zhuǎn)載,授權(quán)轉(zhuǎn)載時(shí)須注明
“來(lái)源:陽(yáng)普醫(yī)療”。本網(wǎng)所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來(lái)源和作者,不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們聯(lián)系,我們將立即進(jìn)行刪除處理。
網(wǎng)友評(píng)論:
版主信息
昵稱(chēng):Mandy Luo
郵箱:mandyluo@improve-medical.com
相關(guān)閱讀
- > 《醫(yī)學(xué)拾萃》2023年12月刊:簡(jiǎn)述實(shí)驗(yàn)室信息管理系統(tǒng)發(fā)展歷程
- > 《醫(yī)學(xué)拾萃》2023年10月刊:分析前標(biāo)本處理對(duì)神經(jīng)元特異性烯醇化酶(NSE)檢測(cè)的影響
- > 《醫(yī)學(xué)拾萃》2023年8月刊:PSA 檢測(cè)的標(biāo)本處理、質(zhì)量控制及其臨床應(yīng)用
- > 《醫(yī)學(xué)拾萃》2023年6月刊:真空采血管標(biāo)本放置時(shí)間和溫度對(duì)常見(jiàn)檢驗(yàn)項(xiàng)目的影響
- > 《醫(yī)學(xué)拾萃》2023年4月刊:游離 DNA 管使用現(xiàn)狀與展望
- > 《醫(yī)學(xué)拾萃》2023年2月刊:肝素管的臨床適用檢測(cè)項(xiàng)目與不適用項(xiàng)
- > 《醫(yī)學(xué)拾萃》2022年12月刊:血清分離技術(shù)及其對(duì)臨床生化檢驗(yàn)結(jié)果的影響
- > 《醫(yī)學(xué)拾萃》2022年10月刊:標(biāo)本處理對(duì)心肌肌鈣蛋白測(cè)定的影響
- > 《醫(yī)學(xué)拾萃》2022年8月刊:一種新型材料-水凝膠的合成及其應(yīng)用
- > 《醫(yī)學(xué)拾萃》2022年6月刊:RFID 技術(shù)及其在醫(yī)療和標(biāo)本管理中的應(yīng)用與發(fā)展